According to the phase 3 SCIENCE trial, neoadjuvant chemoradiotherapy with or without sintilimab significantly improved pathological complete response rates compared with neoadjuvant chemotherapy with sintilimab for patients with esophageal squamous cell carcinoma.
The Roberts Proton Therapy Center at Penn Medicine celebrated its 15th anniversary on January 24, 2025.
Marcia Cruz-Correa, MD, PhD, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico, comments on the potential of combining multiple biomarkers for early…
A 100% virtual, week-long meeting highlighting the most important developments in oncology each year, delivered by some of the world’s leading oncologists in a multidisciplinary…
Nature Reviews Cancer – CRISPR screens in cell cultures reveal cancer dependencies yet often miss the metabolic nuances of tissues. In this Comment, Zuber and…
An investigational blood test accurately detected colorectal cancer in a study involving more than 27,000 participants. If widely implemented, the test could increase screening adherence…
Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on…
Burnout in health care professionals (HCPs) results from exposure to psychosocial risks at work. Left unaddressed, burnout can lead to chronic health problems, increased staff…
The goals of this CME program are to increase awareness among clinicians about the need for comprehensive cancer survivorship care and specific areas where improved…
Profiling the developing brain enabled rationally guided modeling of FOXR2-activated CNS neuroblastoma, providing a strategy to overcome the heterogeneous origins of pediatric brain tumors that…
